President Donald Trump’s administration has agreed to spend billions of dollars to develop and purchase a possible vaccine. And the government launched "Fast completion process"It is an inter-ministerial program to accelerate the manufacture of vaccines, medicines and diagnostics Corona virus infection.
There are more than 150 vaccines for the Coronavirus, which depend on a variety of technologies being developed globally, including about twenty in the clinical trial phase. The government has signed agreements with drug companies to ensure access to various candidate vaccines.
The goal is Production of vaccines It can eliminate the pandemic by protecting billions of people from infection or severe disease.
The candidate vaccine from Pfizer and Bayot.Netc is among the vaccines to be tested in a wide test. The vaccine showed promising early-stage results with small studies in humans.
Pfizer will deliver the doses when the product obtains a permit for emergency use or a license from US Food and Drug Administration After meeting safety and efficacy standards in a broad clinical trial, stage three.
The companies said they expected to be ready to request some form of licensing early in October if the ongoing studies were successful.
Pfizer and BayouNTC are now forecasting to manufacture up to 100 million doses globally by the end of 2020, and possibly more than 1.3 million doses by the end of 2021.
Pfizer shares rose 4 percent, while US-listed Bio NTC shares jumped nearly 6 percent before the close.
“>
The Department of Health and Human Services and the Department of Defense said the agreement allows the US government to obtain an additional 500 million doses.
President Donald Trump’s administration has agreed to spend billions of dollars to develop and purchase a possible vaccine. The government launched the “rapid delivery process”, an inter-ministerial program to accelerate the manufacture of vaccines, medicines and diagnostics Corona virus infection.
There are more than 150 vaccines for the Coronavirus, which depend on a variety of technologies being developed globally, including about twenty in the clinical trial phase. The government has signed agreements with drug companies to ensure access to various candidate vaccines.
The goal is Production of vaccines It can eliminate the pandemic by protecting billions of people from infection or severe disease.
The candidate vaccine from Pfizer and Bayot.Netc is among the vaccines to be tested in a wide test. The vaccine showed promising early-stage results with small studies in humans.
Pfizer will deliver the doses when the product obtains a permit for emergency use or a license from US Food and Drug Administration After meeting safety and efficacy standards in a broad clinical trial, stage three.
The companies said they expected to be ready to request some form of licensing early in October if the ongoing studies were successful.
Pfizer and BayouNTC are now forecasting to manufacture up to 100 million doses globally by the end of 2020, and possibly more than 1.3 million doses by the end of 2021.
Pfizer shares rose 4 percent, while US-listed Bio NTC shares jumped nearly 6 percent before the close.
–
